Published in Biochem Pharmacol on December 11, 2009
Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int J Radiat Biol (2011) 0.89
KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells. Biochem Pharmacol (2011) 0.84
Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo. Radiat Res (2012) 0.80
Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency. Radiat Oncol (2011) 0.80
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells. Bioorg Med Chem Lett (2013) 0.77
Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine. J Med Chem (2013) 0.76
A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions. Chem Biol Drug Des (2012) 0.75
Key role of hydrazine to the interaction between oxaloacetic against phosphoenolpyruvic carboxykinase (PEPCK): ONIOM calculations. J Mol Model (2013) 0.75
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (2001) 8.57
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer (2008) 6.02
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell (2009) 5.91
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol (1995) 3.53
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
Hypoxic gene expression and metastasis. Cancer Metastasis Rev (2004) 2.01
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res (1981) 1.59
Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res (1988) 1.54
In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy. Lab Anim Sci (1977) 1.49
Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol (2000) 1.37
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci U S A (2005) 1.15
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res (2005) 1.13
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res (2004) 1.08
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res (2008) 1.06
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther (2006) 1.05
Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J Med Chem (1999) 1.04
Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem (1990) 1.04
Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein. Anal Biochem (2008) 1.00
The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem (1998) 1.00
Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species. Leuk Res (2008) 0.97
Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. IDrugs (2009) 0.81
Laromustine: the return of alkylators to non-myeloablative therapy of AML. Leuk Res (2009) 0.80
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest (2007) 2.03
Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys (2005) 1.44
Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells. Leuk Res (2007) 1.37
Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem (2004) 1.20
1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci U S A (2005) 1.15
Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk? Cell Cycle (2008) 1.14
The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res (2005) 1.13
Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Int J Cancer (2004) 1.12
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst (2011) 1.11
The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res (2007) 1.08
Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells. Radiat Res (2008) 1.06
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther (2006) 1.05
Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol (2006) 1.03
Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU. Biochem Pharmacol (2005) 1.03
Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol (2007) 1.03
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase. Biochem Pharmacol (2010) 1.02
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res (2009) 1.01
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther (2005) 1.01
Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol (2004) 1.01
Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein. Anal Biochem (2008) 1.00
Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species. Leuk Res (2008) 0.97
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol (2012) 0.94
Targeted ablation of Abcc1 or Abcc3 in Abcc6(-/-) mice does not modify the ectopic mineralization process. Exp Dermatol (2007) 0.93
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. J Soc Gynecol Investig (2006) 0.91
Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer? Oncol Res (2008) 0.91
Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/apoptosis--dimethylsulfoxide, hexamethylene bisacetamide and trichostatin A. Eur J Biochem (2004) 0.90
Nuclear overexpression of NAD(P)H:quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions. J Biol Chem (2004) 0.89
Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int J Radiat Biol (2011) 0.89
Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer (2002) 0.89
Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol (2011) 0.87
Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochem Pharmacol (2004) 0.87
Structure and function converge to identify a hydrogen bond in a group I ribozyme active site. Angew Chem Int Ed Engl (2009) 0.87
Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts. Mol Cancer Ther (2002) 0.87
Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain. ChemMedChem (2013) 0.87
Bioactivation and resistance to mitomycin C. Methods Enzymol (2004) 0.87
Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. Kidney Int (2010) 0.85
KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells. Biochem Pharmacol (2011) 0.84
Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W. Chem Res Toxicol (2014) 0.82
Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-induced albuminuria and glomerulosclerosis. Nephron Exp Nephrol (2010) 0.82
7-Nitro-4-(phenylthio)benzofurazan is a potent generator of superoxide and hydrogen peroxide. Arch Toxicol (2012) 0.82
Role of caspase activation in butyrate-induced terminal differentiation of HT29 colon carcinoma cells. Arch Biochem Biophys (2004) 0.81
Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells. Nucleic Acids Res (2004) 0.81
Prevention and regression of hypertension: role of renal microvascular protection. Hypertens Res (2009) 0.80
Influence of glutathione and glutathione S-transferases on DNA interstrand cross-link formation by 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, the active anticancer moiety generated by laromustine. Chem Res Toxicol (2014) 0.80
Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase. Bioorg Med Chem Lett (2012) 0.80
Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo. Radiat Res (2012) 0.80
Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res (2004) 0.80
Expression of O(6)-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue. J Cancer Ther (2013) 0.79
Identification of a splice variant of mouse caveolin-2 mRNA encoding an isoform lacking the C-terminal domain. Arch Biochem Biophys (2002) 0.79
Overexpression of heat shock factor 1 inhibits butyrate-induced differentiation in colon cancer cells. Cell Stress Chaperones (2006) 0.79
Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth. J Antimicrob Chemother (2006) 0.78
Nuclear localization of NADPH:cytochrome c (P450) reductase enhances the cytotoxicity of mitomycin C to Chinese hamster ovary cells. Mol Pharmacol (2004) 0.78
Modulation of Wnt-specific colon cancer cell kill by butyrate and lithium. Oncol Res (2004) 0.78
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells. Bioorg Med Chem Lett (2013) 0.77